Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585190 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL19357562 | 0.85 | MTNR1A (0.53) | ADRB2ADRB1ALDH1A1LMNARECQL | |
| SCHEMBL3573224 | 0.84 | ADRB2 (0.47) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL3573225 | 0.84 | ADRB2 (0.47) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL3574069 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2ADRB2ADRB1L3MBTL1POLB | |
| SCHEMBL3580415 | 0.82 | KMT2A (0.52) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL3578459 | 0.78 | MEN1 (0.44) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL15958920 | 0.77 | ADRB2 (0.59) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL3571485 | 0.76 | POLB (0.68) | SMN1; SMN2KMT2AALDH1A1LMNAHTT | |
| SCHEMBL1496789 | 0.75 | TSHR (0.71) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | SMN1; SMN2 891/4885ADRB2 405/4885ADRB1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.